Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study

Objectives: Regarding reactogenicity and immunogenicity, heterologous COVID-19 vaccination regimens are considered as an alternative to conventional immunization schemes. Methods: Individuals receiving either heterologous (ChAdOx1-S [AstraZeneca, Cambridge, UK]/BNT162b2 [Pfizer-BioNTech, Mainz, Germ...

Full description

Bibliographic Details
Main Authors: Niko Kohmer, Shivana Stein, Barbara Schenk, Katharina Grikscheit, Melinda Metzler, Holger F. Rabenau, Marek Widera, Eva Herrmann, Sabine Wicker, Sandra Ciesek
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:International Journal of Infectious Diseases
Subjects:
Heterologous prime-boost
ChAdOx1-S
BNT162b2
Immunogenicity
Reactogenicity
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971222006725

Internet

http://www.sciencedirect.com/science/article/pii/S1201971222006725

Similar Items